©Author(s) (or their employer(s)) 2026.
World J Gastroenterol. Mar 7, 2026; 32(9): 114200
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.114200
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.114200
Figure 6 Potential of perioperative carcinoembryonic antigen in guiding treatment decision making.
A-D: Kaplan-Meier curves of overall survival (OS) and disease-free survival (DFS) for patients without adjuvant chemotherapy in the training cohort, grouping based on pre-CEA (A and B), grouping based on post-CEA (C and D); E-H: Kaplan-Meier curves of OS and DFS for patients without adjuvant chemotherapy in the validation cohort, grouping based on pre-CEA (E and F),grouping based on post-CEA (G and H).
- Citation: Du FQ, Liu JL, Mai LD, Han XH, Song WJ, Yang D, Zhang QJ, Zhang R, Liu YL, Tong JX. Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer. World J Gastroenterol 2026; 32(9): 114200
- URL: https://www.wjgnet.com/1007-9327/full/v32/i9/114200.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i9.114200